128196-02-1

Basic information

• Product Name: (R)-(-)-CITALOPRAM
• Synonyms: (R)-(-)-CITALOPRAM
• CAS NO: 128196-02-1
• Molecular Formula: C₂₀H₂₁FN₂O
• Molecular Weight: 324.39
• Mol File: 128196-02-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 428.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• PKA: 9.57±0.28(Predicted)
• CAS DataBase Reference: (R)-(-)-CITALOPRAM(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-CITALOPRAM(128196-02-1)
• EPA Substance Registry System: (R)-(-)-CITALOPRAM(128196-02-1)

Safety Data

• Hazardous Substances Data: 128196-02-1(Hazardous Substances Data)

Usage

Uses

(R)-(-)-Citalopram is an antidepressant of selective serotonin reuptake inhibitor (SSIR) class. Citalopram is used in the treatment of major depressive disorder.

Definition

ChEBI: A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has R-configuration at the chiral centre. It is the inactive enantiomer of citalopram.

Upstream product

• 219861-18-4 (R)-(+)-4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile 
• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 
• 128173-53-5 (-)4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(3-hydroxymethyl)-benzonitrile hemi (+)-di-p-toloyltartaric acid salt 
• 166037-77-0 (-)-Didemethylcitalopram 
• 50-00-0 formaldehyd 
• 64-18-6 formic acid 

Downstream Products

• 227954-87-2 C₂₀H₂₂FNO₂ 
• 1329745-98-3 (R)-4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)-1-butanone 
• 917482-45-2 (-)-Citalopram N-oxide 
• 144010-85-5 (-)-Desmethylcitalopram 

Relevant articles and documents

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

Response to the comments by Elati et al. in response to our article examining one of their previous articles

This reply highlights and discusses what we observe as internal inconsistencies in the data and analysis presented by Elati and coauthors in conjunction with their resolution protocols, as well as inconsistencies between their original manuscript, the ass

PREPARATION OF ESCITALOPRAM

Enantiomerically enriched citalopram is prepared by methylating enantiomerically enriched didesmethylcitalopram, obtained by directly resolving racemic didesmethylcitalopram using a chiral acid.